Forum (Forum & Focus)
Jun. 29, 2009
Pay for Delay
Health care, patent and antitrust laws are colliding in cases of branded drug companies paying potential generic competitors to stay out of the market, writes Dan Mogin.
FORUM COLUMN
By Dan Mogin The Hatch-Waxman Act was enacted in 1984 to promote generics while preserving a financial incentive for research and development through patent extension. Likewise, the patent laws are designed to promote innovation and invention by granting a limited term monopoly. The antitrust laws are designed to promote competition so that market participants, including businesses and ordinary consumers, have economic choices and rec...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In